New: Clinical trial search, funded by the National Cancer InstituteNew: NCI-funded clinical trial search

How do you approach treatment of HIV-positive DLBCL with low ejection fraction?

Ask a clinical question

Answers grounded in the literature and physician expertise.

Related Questions

Has the data for the ENRICH study changed your practice for the initial treatment of mantle-cell lymphoma?

How have the results of the SUNMO trial with mosunetuzumab/polatuzumab vedotin impacted your treatment choices for transplant ineligible relapsed/refractory DLBCL?

For patients with relapsed/refractory follicular lymphoma receiving mosunetuzumab, when, if ever, would you consider transitioning from intravenous to subcutaneous administration?

About Mednet

A community where doctors find answers to medicine's toughest questions.

Verified, credentialed physicians
45,000+ members across 23 specialties
Free CME and MOC credit

Evidence Meets Expertise

Community

Browse Specialties
Code of Conduct
AI Community Guidelines

Tools

Mednet AI
TrialMatch
Mobile App

Company

About
Careers
Events
Our Work
Blog

Support

FAQs
Contact Us
Programs

Legal

Privacy Policy
Terms of Service

© 2026 Mednet Inc. All rights reserved.